S-1/A: Jupiter Neurosciences Eyes Nasdaq Listing with $11 Million IPO, Focus on Parkinson's Treatment

Jupiter Neurosciences is seeking to raise capital through an IPO to advance its JOTROL drug, particularly for Parkinson's disease, and expand into the South-East Asian market.

Summary

• Jupiter Neurosciences, Inc., a clinical-stage pharmaceutical company, is planning an initial public offering (IPO) to raise capital for the development of its drug candidate, JOTROL.
• The company is offering 2,750,000 shares of common stock with an expected price range of $4.00 to $5.00 per share.
• The IPO aims to list the company's common stock on the Nasdaq Capital Market under the ticker symbol 'JUNS'.
• A portion of the IPO proceeds will be used to repay debt, fund research and development activities, and support a clinical trial of JOTROL in patients with Parkinson's disease.
• The company also intends to use proceeds to establish a presence in South-East Asia through service agreements.
• Jupiter Neurosciences is developing JOTROL, a resveratrol-based drug, for neuro-inflammatory conditions, including rare diseases and larger indications like Parkinson's and Alzheimer's.
• The company has completed preclinical activities in a mouse model of Parkinson's disease, showing promising results.
• The company has service agreements in place to develop its product in the South-East Asian market.
• The company has an exclusive, worldwide license from Aquanova AG for JOTROL.
• The company has a history of operating losses and expects to continue incurring losses for the foreseeable future, raising substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive aspects such as the potential of JOTROL and the company's strategic approach, the financial risks and uncertainties surrounding the company's ability to continue as a going concern temper the overall outlook.

Positives

• JOTROL has shown promise in preclinical studies, particularly in a mouse model of Parkinson's disease.
• The company has secured an exclusive, worldwide license from Aquanova AG for JOTROL.
• The company has service agreements in place to develop its product in the South-East Asian market.
• The company has identified a potential path to accelerated FDA approval for rare disease indications.
• The company has a Scientific Advisory Board with experience in regulatory affairs and clinical development.

Negatives

• The company has a history of operating losses and expects to continue incurring losses for the foreseeable future.
• The company's auditor has included an explanatory paragraph relating to its ability to continue as a going concern in its audit report for the fiscal years ended December 31, 2023 and 2022.
• The company is substantially dependent on the success of its product candidate, JOTROL.
• The company faces significant competition from other pharmaceutical companies.
• The company relies on third parties to conduct its preclinical studies, clinical trials, and manufacturing.
• The company is planning on entering into a Strategic Service Agreement with DOMINANT TREASURE HEALTH COMPANY LIMITED with respect to strategic services in Asia immediately following the completion of the public offering, the fees payable by the Company pursuant to which, are non-refundable and not tied to any milestones or performance, and the foregoing nature of such fees, could have a material negative impact on our business, financial condition and operating results.

Risks

• The company is early in its development efforts, with a limited operating history, and has no products approved for commercial sale.
• The company will require substantial additional capital to finance its operations.
• The company's substantial amount of indebtedness may adversely affect its cash flow and its ability to operate its business.
• The company is substantially dependent on the success of its product candidate, JOTROL.
• Clinical drug development involves a lengthy and expensive process with an uncertain outcome.
• The company faces significant competition, and if its competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the product candidates we develop, our commercial opportunities will be negatively impacted.
• The price of our common stock could be subject to rapid and substantial volatility.
• Our management has concluded that our historical recurring losses from operations and negative cash flows from operations as well as our dependence on securing private equity and other financings raise substantial doubt about our ability to continue as a going concern and our auditor has included an explanatory paragraph relating to our ability to continue as a going concern in its audit reports for the fiscal years ended December 31, 2023 and 2022.

Future Outlook

The company plans to use the net proceeds from this offering, together with its existing resources, to initiate a Phase II clinical trial with JOTROL in patients with Parkinsons Disease, establish a presence in South-East Asia through service agreements and advancing the manufacturing of JOTROL clinical trial supplies. in support of activities leading up to clinical trials in targeted indications. Remaining proceeds will be used for general research and development activities, working capital and other general corporate activities.

Management Comments

• Management has concluded that our historical recurring losses from operations and negative cash flows from operations as well as our dependence on securing private equity and other financings raise substantial doubt about our ability to continue as a going concern and our auditor has included an explanatory paragraph relating to our ability to continue as a going concern in its audit reports for the fiscal years ended December 31, 2023 and 2022.
• We believe that our structure with a core management team that has experience in the utilization of outside resources makes it possible for us to efficiently execute several programs simultaneously in a cost-effective way.

Industry Context

The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. The company will compete with existing therapies and new therapies that may become available in the future.

Comparison to Industry Standards

• Reata Pharmaceuticals recently received FDA approval for Omaveloxolone for Friedreichs ataxia and was subsequently acquired by Biogen for $7.3 billion.
• Eli Lilly's Donanemab, an investigational antibody for early symptomatic AD, has received FDA Breakthrough Therapy designation and is in Phase 3 trials.
• Eisai and Biogen's Leqembi, an Alzheimer's drug, has received unanimous support from expert advisors for traditional U.S. approval, with a price set at $26,000 per year.

Legal Proceedings

• On July 19, 2022, Tiberend Strategic Advisors (Tiberend), an entity that the Company had previously engaged as a communications and investor relations firm, filed a summons for civil action in the District Court of Southern Florida against the Company alleging non-payment by the Company under a services agreement (the Services Agreement) with Tiberend in the amount of $130,400.

Related Party Transactions

• The Companys Chief Executive Officer (CEO) has loaned the Company working capital since inception.
• Accrued compensation includes partially accrued salaries to executives since inception.
• On July 21, 2022, the Board of Directors executed a Unanimous Written Consent relating to the forgiveness of $1,556,010 of accrued salaries for executives and two consultants.
• On September 29, 2023, the Board of Directors executed a Unanimous Written Consent relating to the forgiveness of accrued compensation for executives, consultants, and board members in the amount of $4,189,626.

Stakeholder Impact

• The company's ability to execute on its business strategy is subject to a number of risks, which are discussed more fully in the section titled Risk Factors beginning on page 16.
• The price of our common stock could be subject to rapid and substantial volatility.
• Our management has concluded that our historical recurring losses from operations and negative cash flows from operations as well as our dependence on securing private equity and other financings raise substantial doubt about our ability to continue as a going concern and our auditor has included an explanatory paragraph relating to our ability to continue as a going concern in its audit reports for the fiscal years ended December 31, 2023 and 2022.

Next Steps

• The company intends to use a portion of the net proceeds from this offering to repay debt, fund research and development activities, and support a clinical trial of JOTROL in patients with Parkinson's disease.
• The company also intends to use proceeds to establish a presence in South-East Asia through service agreements.
• The company plans to apply for a smaller grant, $2.5 million, for a Proof of Concept study focusing on JOTROLs effect on validated biomarker.

Key Dates

Keywords

JOTROL, Parkinson's Disease, Alzheimer's Disease, Resveratrol, IPO, Clinical Trials, Neurosciences, Pharmaceutical, Rare Diseases, South-East Asia